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Abstract
This manuscript introduces an R package called trialr that implements a collection of
clinical trial methods in Stan and R. In this article, we explore three methods in detail.
The first is the continual reassessment method for conducting phase I dose-finding trials
that seek a maximum tolerable dose. The second is EffTox, a dose-finding design that
scrutinises doses by joint efficacy and toxicity outcomes. The third is the augmented
binary method for modelling the probability of treatment success in phase II oncology
trials with reference to repeated measures of continuous tumour size and binary indicators
of treatment failure. We emphasise in this article the benefits that stem from having access
to posterior samples, including flexible inference and powerful visualisation. We hope that
this package encourages the use of Bayesian methods in clinical trials.
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1. Introduction
Clinical trials are sequential medical experiments in humans. Their collective goal is to identify
experimental therapies that offer sufficient benefit to warrant use in standard clinical practice.
Fundamental to this is the estimation of treatment efficacy and safety. Many experimental
designs have been proposed to these ends.
Stan (Carpenter, Gelman, Hoffman, Lee, Goodrich, Betancourt, Brubaker, Li, and Riddell
2016) is a probabilistic programming language allowing full Bayesian inference via Markov
chain Monte Carlo (MCMC) sampling. We present in this article the trialr package imple-
menting several clinical trial designs in R and Stan.
Investigation of safety is the major preoccupation of early phase clinical trials. A typical phase
I trial would conduct a dose-finding experiment to identify a dose of a novel therapy that is
associated with an acceptable adverse event (AE) rate. The term dose here is used loosely to
reflect the general intensity of treatment. In most cases, dose would have the intuitive property
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of reflecting the quantity of a molecule that is administered to the patient in a treatment
window. It could, however, represent the frequency or the duration of administration, or
a combination of the two. It could also contain information on those aspects of several
experimental therapies that are given together.
In many instances, a dose-finding experiment would be designed to incorporate dose escala-
tion, where successively higher doses are sequentially investigated in cohorts of patients. Such
experimental designs typically assess the patient-level presence or absence of dose-limiting tox-
icity (DLT), the manifestation of at least one of potentially many prespecified adverse events
that would be considered sufficiently serious to halt treatment administration. For illustra-
tion, treatment could commence at a low dose for which there is reasonable expectation of
safety. If a sufficiently low number of these patients experience DLT, the dose may be es-
calated for the next group of patients. Dose-finding trials typically continue sequentially,
with successive doses being chosen in response to the outcomes observed thus far. As such,
dose-finding trials are one of the more simple types of adaptive trial, where some treatment
parameter for patients (here, dose) is affected by the outcomes observed in earlier patients.
A key assumption of dose escalation and de-escalation solely with reference to DLT is that a
higher dose is more likely to provide clinical benefit. A higher dose is accepted as being more
attractive than a lower dose so long as both are associated with an acceptable rate of DLT,
without any reference to the level of efficacy expected or observed. Logic, and the toxicologists’
adage sola dosis facit venenum or the dose makes the poison, dictate that the probability of
toxicity increases in dose. These so-called monotonicity assumptions are the cornerstones of
traditional phase I dose-finding. The highest dose with predicted DLT probability less than
or close to some target rate is referred to as the maximum tolerable dose (MTD).
Identification of the MTD is a typical objective of phase I trials. There are several exper-
imental designs proposed to achieve this goal. The most common is 3+3 (Carter 1973), a
simple algorithm that provides rules for changing dose based on the DLT outcomes of cohorts
of 3 patients. It has been widely criticised for its relatively poor operating performance, its
non-statistical nature, and its lack of flexibility (O’Quigley, Pepe, and Fisher 1990; O’Quigley
and Zohar 2006; Iasonos, Wilton, Riedel, Seshan, and Spriggs 2008; Le Tourneau, Lee, and
Siu 2009). Despite this, it stubbornly persists as the most frequently used dose-finding design
(Rogatko, Schoeneck, Jonas, Tighiouart, Khuri, and Porter 2007; Chiuzan, Shtaynberger,
Manji, Duong, Schwartz, Ivanova, and Lee 2017), due in no small part to its simplicity and
familiarity.
There are also many statistical designs that seek the MTD (O’Quigley et al. 1990; Tighiouart
and Rogatko 2010; Ji and Wang 2013, amongst others). The Continual Reassessment Method
(CRM) by O’Quigley et al. (1990) is particularly noteworthy because of the great amount
of innovation it has facilitated, including the time-to-event CRM (TITE-CRM) approach
(Cheung and Chappell 2000) for studying late-onset toxic events.
Modern cancer drugs like targeted therapies and immunotherapies do not necessarily support
the monotonic efficacy assumption. For instance, two doses of the immunotherapy drug
pembrolizumab that differed by a factor of five were shown in a large randomised trial to
have very similar response rates (Herbst, Baas, Kim, Felip, Pe´rez-Gracia, Han, Molina, Kim,
Arvis, Ahn, Majem, Fidler, De Castro, Garrido, Lubiniecki, Shentu, Im, Dolled-Filhart, and
Garon 2016). When conducting dose-finding in therapies like these, there may be motivation
to scrutinise doses by efficacy and toxicity outcomes. There are several designs that perform
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this task (Braun 2002; Thall and Cook 2004; Zhang, Sargent, and Mandrekar 2006; Wages
and Tait 2015).
Traditional phase II trials take the dose recommended in phase I and investigate early signs
of treatment activity or efficacy. The objective here is to screen out treatments that are
obviously ineffective. These trials can generally be single-arm or randomised. The onus is on
conducting the trial and disseminating the results quickly so that onward clinical research can
proceed promptly. As such, sample sizes tend to be small and outcomes that can be assessed
over the short-term are generally preferred.
Finally, phase III trials seek to provide evidence good enough to affect medical practice. Most
commonly, phase III trials test whether an experimental treatment is superior to the current
standard of care. These trials commonly randomise patients to one of several treatment arms,
use clinically-relevant long-term outcome measures, and have large sample sizes.
Bayesian methods in clinical trials are used predominantly, although not exclusively, in phases
I and II. This is due in part to the limited amount of information available from the low
sample sizes used. Using prior information to complement an analysis can be desirable, and
the model-based methods can benefit computationally from the Bayesian approach.
In this article, we focus on three clinical trial models implemented in trialr under the Bayesian
paradigm using R and Stan:
• the CRM and TITE-CRM models for traditional toxicity-oriented dose-finding;
• the EffTox model for efficacy and toxicity dose-finding;
• the Augmented Binary (AugBin) method (Wason and Seaman 2013) for analysing di-
chotomous response in phase II cancer trials whilst retaining the continuous information
in measurements of tumour size.
There are several other R-packages that implement the Bayesian CRM in R, including dfcrm
(Cheung 2013, 2011), bcrm (Sweeting, Mander, and Sabin 2013), and crmPack (Sabanes
Bove, Yin Yeung, Palermo, and Jaki 2018). dfcrm uses a non-MCMC approach. bcrm and
crmPack support MCMC via JAGS and WinBUGS. To the best of our knowledge, trialr is the
only package on CRAN to implement the CRM and EffTox in Stan, and the only package on
CRAN to implement the AugBin method.
To avoid large-scale repetition of material in previous publications on CRM software (Sweeting
et al. 2013; Cheung 2011), we focus the dose-finding aspects of this article on functions related
to dose transtion pathways (Yap, Billingham, Cheung, Craddock, and O’Quigley 2017; Brock,
Billingham, Copland, Siddique, Sirovica, and Yap 2017), a tool to aid trial planning. This
approach is considered for both the CRM and EffTox designs. Then we introduce the AugBin
method for single arm trials with two post-baseline analyses.
trialr was first added to CRAN in 2017 with Stan implementations of EffTox, a hierarchical
model for analysing responses to a single drug in several related subtypes of a disease (Thall,
Wathen, Bekele, Champlin, Baker, and Benjamin 2003), and a joint-model for analysing
co-primary efficacy and toxicity outcomes when baseline covariate information is available
(Brock 2019). Successive updates have seen the addition of the CRM and AugBin models.
trialr relies heavily on tidyverse (Wickham 2017) packages to create a modern workflow in R
for Bayesian approaches to clinical trials.
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model Link function Parameters
empiric F (d, β) = dexpβ normal prior on β
logistic F (d, β) = 1/(1 + exp (−a0 − exp (β)d)) a0 fixed, normal prior on β
logistic_gamma F (d, β) = 1/(1 + exp (−a0 − βd)) a0 fixed, gamma prior on β
logistic2 F (d, α, β) = 1/(1 + exp (−α− exp (β)d)) normal priors on α and β
Table 1: CRM models implemented in trialr.
2. Methodology
2.1. CRM
The Continual Reassessment Method (CRM) was originally published by O’Quigley et al.
(1990) to conduct dose-finding trials seeking a maximum tolerable dose (MTD). It is a truly
seminal design, with many variants appearing over the years to handle different clinical sce-
narios, such as related groups (O’Quigley and Paoletti 2003), late-onset toxicity (Cheung and
Chappell 2000), efficacy and toxicity outcomes (Braun 2002; Zhang et al. 2006), and more. In
this section, we focus on the original Bayesian design that seeks the MTD in an homogeneous
patient group.
In a trial of doses d1, ..., dK , the investigators provide their best guess of the probability of
DLT at each dose to create a toxicity skeleton (p1, ..., pK). CRM assumes monotonically
increasing toxicity risk so we stipulate that p1 < ... < pK .
The probability of DLT at dose x is modelled to be F (x, θ), where F is a smooth mathematical
function, and θ is a general vector of parameters. Different variants of this model use different
forms for F , and different prior distributions on θ. The CRM variants currently implemented
in trialr are listed in Table 1.
To ensure that the probability of toxicity increases with dose, the slope parameter β is expo-
nentiated in some of the models in Table 1. In the model with gamma prior, this step is not
necessary because the prior constrains the posterior to admit only positive values.
For the purposes of statistical modelling, the explanatory dose variables dk are codified such
that
pk = F (dk, θˆ),
where θˆ is the vector of prior expected values of the elements of θ. That is, the dk are derived
so that using the prior expected value of each model parameter, the prior expected probability
of DLT at dk is pk. Cheung (2011) calls the dk dose-labels to distinguish them from the actual
dose units like “10 mg” that a clinician might actually administer to a patient.
For patient i, let Yi be a random variable taking values {0, 1} reflecting the absence and
presence of DLT, and xi ∈ {d1, ..., dK} be the dose administered. After the evaluation of I
patients, the aggregate likelihood is:
LI(θ) =
I∏
i=1
{F (xi, θ)}Yi {1− F (xi, θ)}1−Yi
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This quantity can either be maximised with respect to θ to obtain the maximum likelihood
estimate, or augmented with priors and analysed in a Bayesian way. CRM was originally
published as a Bayesian design and that is the approach we take in trialr using Stan.
Cheung and Chappell (2000) introduced the notion of weighting the Yi to reflect the extent
to which they have been evaluated. For instance, if a patient is 50% of the way through
the evaluation period without having yet experienced toxicity, we might interpret them as
providing an observation Yi = 0 with weight 0.5. This leads to the weighted likelihood
statement:
LI(θ) =
I∏
i=1
{wiF (xi, θ)}Yi {1− wiF (xi, θ)}1−Yi ,
as used in the TITE-CRM design. This insight faciltated the study of long-term toxicity
events, without the requirement that each patient complete the evaluation period before they
contribute information to the dose selection decision.
CRM models are accessed in trialr primarily through the stan_crm function, as described
below.
2.2. EffTox
The EffTox design (Thall and Cook 2004; Thall, Cook, and Estey 2006; Thall, Herrick,
Nguyen, Venier, and Norris 2014) conducts dose-finding clinical trials where both efficacy
and toxicity events guide dose selection. This contrasts methods like 3+3 and CRM where
dose selection is determined by toxicity events only. It is no longer assumed that higher doses
are implicitly more likely to be beneficial to patients. Instead, EffTox calculates attractiveness
or utility scores for doses that trade-off the estimated probabilities of efficacy and toxicity.
The design iteratively seeks the dose with the highest utility score. We will call this the
optimum biological dose (OBD) to distinguish it from the MTD and the pratice of escalating
under assumed montonically increasing efficacy. When recommending the next dose, EffTox
does not blindly recommend the prevailing OBD. Instead, it uses rules that forbid the skip-
ping of untested doses. Full details are given in the authors’ publications but we provide a
brief recap of the statistical methodology here.
For doses (y1, ..., yn), the authors define standardised doses (x1, ..., xn) using the transform
xj = log yj −
n∑
k=1
log yk
n
The model uses six parameters, θ = (α, β, γ, ζ, η, ). At dose x, the marginal probabilities of
toxicity and efficacy are estimated by the logit models:
logit piT (x, θ) = α+ βx
and
logit piE(x, θ) = γ + ζx+ ηx
2
Let Y = (YE , YT ) be indicators of binary efficacy and toxicity events and let pia,b(x, θ) =
Pr(YE = a, YT = b|x, θ) for a, b ∈ {0, 1}. The efficacy and toxicity events are associated by
the joint probability function
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pia,b(x, θ) = (piE)
a(1− piE)1−a(piT )b(1− piT )1−b + (−1)a+b(piE)(1− piE)(piT )(1− piT )e
ψ − 1
eψ + 1
,
where ψ is a parameter that measures the strength of association between the co-primary
outcomes, and (x, θ)-notation has been suppressed on the right-hand side for brevity. Normal
priors are specified for the elements of θ.
Let D represent the trial data collected hitherto. At each dose update decision, the dose x is
acceptable if
Pr {piT (x,θ) < piT |D} > pT ,
Pr {piE(x,θ) > piE |D} > pE
and is no more than than one position below the lowest dose-level given and no more than
one position above the highest dose-level given. The effect of these last two criteria is that
untried doses may not be skipped in escalation or de-escalation. The values piE and piT are
provided by the investigators with reference to what is acceptable in the clinical scenario,
given the set of alternative treatments. Thall and Cook (2004) selected pE = pT = 0.1 so
that doses were excluded from the acceptable set only if we are very sure that they are either
inactive or excessively toxic.
The utility of dose x, with efficacy piE(x, θ) and toxicity piT (x, θ) is
u(piE , piT ) = 1−
((
1− piE
1− pi∗1,E
)p
+
(
piT
pi∗2,T
)p) 1p
where p is calculated to intersect the points (pi∗1,E , 0), (1, pi
∗
2,T ) and (pi
∗
3,E , pi
∗
3,T ) in the efficacy-
toxicity plane. We will refer to these as hinge points but that is not nomenclature used by
the authors.
At the dose selection decision, the dose-level from the subset of doses that are acceptable with
maximal utility is selected to be given to the next patient or cohort. If there are no acceptable
doses, the trial stops and no dose is recommended.
There are several published EffTox examples, including explanations and advice on parameter
choices (Thall and Cook 2004; Thall et al. 2006, 2014; Brock et al. 2017).
The MD Anderson Cancer Center publishes software1 to perform calculations and simulations
for EffTox trials. The software is available for Windows in compiled-form. Thus, trialists can-
not run the software on Mac or Linux unless via a virtual machine or emulator. Furthermore,
they may not alter the behaviour of the model. Brock et al. (2017) describe a clinical trial
scenario where some alteration to the default model behaviour would have been preferable.
It was this that prompted the author to write the open-source implementation provided in
trialr.
2.3. Augmented Binary method
1see https://biostatistics.mdanderson.org/SoftwareDownload/SingleSoftware/Index/2
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In oncology clinical trials, tumours are often measured at baseline and repeatedly post-baseline
to gauge the response to therapy. The Response Evaluation Criteria in Solid Tumors (RE-
CIST)(Eisenhauer, Therasse, Bogaerts, Schwartz, Sargent, Ford, Dancey, Arbuck, Gwyther,
Mooney, Rubinstein, Shankar, Dodd, Kaplan, Lacombe, and Verweij 2009) define an algo-
rithm for classifying into categories the tumour measurements compared to baseline. Up to
five so-called target lesions are identified at baseline and the sum of their largest diameters
is recorded. A complete response is said to have occurred post-baseline when all tumour le-
sions disappear. A partial response occurs when the aggregate diameter of the target lesions
shrinks by at least 30% and no new lesions are detected. Commonly, the complete and par-
tial response events are combined to form an objective response category, and this is used to
calculate the binary response rate in a trial.
Statisticians are aware that this dichotomisation of a continuous underlying measure leads to
information loss and less efficient analysis. However, responder analysis is endemic in cancer
trials. In response, Wason and Seaman (2013) introduced the Augmented Binary model. It
analyses the continuous log-tumour size ratio, whilst building in mechanisms for so-called
non-shrinkage failures that signal lack of success, such as the manifestation of new lesions,
even if requisite tumour shrinkage is observed. Wason & Seaman introduced versions of their
model for single-arm and randomised groups trials. We describe here the single-arm variant.
Let z0i be the tumour size at baseline for patient i, z1i the size at interim, and z2i the size at
the end of the trial. Let (y1i, y2i) = (log (z1i/z0i), log (z2i/z0i)) be the log tumour size ratios
with respect to baseline. Furthermore, the authors define variables D1i and D2i to represent
the observation of non-shrinkage failure at interim and final assessments. Finally, they define
Si to be a composite success indicator. Using 30% shrinkage as the threshold for success,
Si = 1 if D1i = D2i = 0 and y2i < log (0.7).
The authors specify the following statistical models. The tumour shrinkage variables are
modelled using a bivariate normal distribution:
(y1i, y2i)
T ∼ N ((µ1i, µ2i)T ,Σ) ,
where µ1i = α+ γz0i and µ2i = β + γz0i, and Σ is assumed to be unstructured.
The non-shrinkage failures are estimated using logit models:
logit Pr(D1i = 1|Z0i) = αD1 + γD1z0i
and
logit Pr(D2i = 1|D1i = 0, Z0i, Z1i) = αD2 + γD2z1i.
Finally,
Pr(Si = 1|z0i, θ) =
∫ ∞
−∞
∫ ∞
−∞
Pr(Si = 1|z0i, y1i, y2i, θ)fY1,Y2(y1i, y2i)dy1idy2i.
In their paper, Wason & Seaman fit the model using the R functions gls and glm, and used
cubature to resolve the double integral above. In trialr, we provide priors on the elements of
8 trialr: Bayesian Clinical Trial Designs in R and Stan
θ and sample from the posterior using Stan.
3. Using trialr
3.1. Describing outcomes in dose-finding trials
In the following sections, we will make frequent use of the following scheme for describing
outcomes in dose-finding trials. In situations where toxicity only is being assessed, as with
CRM, we will use the characters T and N to represent the outcomes toxicity and no-toxicity.
We will string these characters behind integer dose-levels to represent the outcomes of patients
in cohorts treated at a dose. For instance, the string 1NNN 2TNT represents the outcomes of
six patients, treated in two cohorts of three. The first cohort was treated at dose-level 1 and
none of the patients had toxicity. The second cohort received dose-level 2 and two of the three
experienced toxicity.
In the setting where efficacy and toxicity outcomes are valuated, as with EffTox, we use
the characters E, T, B, and N to represent the outcomes efficacy only, toxicity only, both and
neither. Again, we string these characters behind integer dose-levels to represent cohorts. The
string 1NN 2EB represents the outcomes of two cohorts of two patients. The second cohort
was treated at dose-level 2 and both experienced the efficacy event, but one of the two also
experienced toxicity.
This syntax was originally described in the context of an EffTox trial (Brock et al. 2017). It
is used in trialr to describe outcomes in dose-finding trials.
3.2. CRM
The core function for fitting a CRM model in trialr is stan_crm. To demonstrate usage, we
will fit a model to the scenario described by Cheung (2011, p. 21).
In a five-dose scenario, they seek the dose associated with the target toxicity level 25% using
the initial toxicity skeleton (5%, 12%, 25%, 40%, 55%). They use a one-parameter logistic
model with intercept fixed at 3 and a N(0, 1.34) prior distribution on β. In their scenario,
they have already evaluated five patients at dose-levels 3, 4 and 5 with outcomes 3N 5N 5T
3N 4N and they want to know the dose recommended by the model for the sixth patient.
R> library(trialr)
R>
R> skeleton <- c(0.05, 0.12, 0.25, 0.40, 0.55)
R> target <- 0.25
R> fit <- stan_crm(outcome_str = '3N 5N 5T 3N 4N',
R+ skeleton = skeleton, target = target,
R+ model = 'logistic', a0 = 3,
R+ beta_mean = 0, beta_sd = sqrt(1.34),
R+ seed = 123, refresh = 0)
R>
R> fit
Patient Dose Toxicity Weight
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1 1 3 0 1
2 2 5 0 1
3 3 5 1 1
4 4 3 0 1
5 5 4 0 1
Dose Skeleton N Tox ProbTox MedianProbTox ProbMTD
1 1 0.05 0 0 0.0343 0.00833 0.043
2 2 0.12 0 0 0.0697 0.02838 0.074
3 3 0.25 2 0 0.1371 0.08599 0.161
4 4 0.40 1 0 0.2295 0.18900 0.246
5 5 0.55 2 1 0.3507 0.34000 0.476
The model targets a toxicity level of 0.25.
The dose with estimated toxicity probability closest to target is 4.
The dose most likely to be the MTD is 5.
Model entropy: 1.32
trialr currently supports models listed in Table 1. The choice of model determines what model
parameters are required. We see above that the logistic model requires the parameter a0
for the fixed intercept, and beta_mean and beta_sd parameters to describe the prior on β.
In contrast, the logistic2 parameterisation requires prior hyperparameters on α and β. See
? stan_crm for full details.
Extra parameters in calls to stan_crm are passed onwards via the ... operator to the
function in rstan that performs the MCMC sampling, rstan::sampling. The parameter
choice seed = 123 allows reproducible sampling. The effect of refresh = 0 is to suppress
the log messages created by Stan.
The object returned by stan_crm has type crm_fit, which subclasses the type dose_finding_fit.
Its default print method displays a table of patient-level information, followed by a table of
dose-level information, followed by some summary information. ProbTox is the posterior mean
probability of toxicity at each dose calculated from the full posterior distributions.
trialr works with tidybayes (Kay 2019) so that posterior samples are simple to access and
flexible to work with.
R> library(dplyr)
R> library(tidybayes)
R> fit %>%
R+ gather_draws(prob_tox[dose]) %>%
R+ head
# A tibble: 6 x 6
# Groups: dose, .variable [5]
.chain .iteration .draw dose .variable .value
<int> <int> <int> <int> <chr> <dbl>
1 1 1 1 1 prob_tox 0.0103
2 1 1 1 2 prob_tox 0.0339
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3 1 1 1 3 prob_tox 0.0986
4 1 1 1 4 prob_tox 0.209
5 1 1 1 5 prob_tox 0.363
6 1 2 2 1 prob_tox 0.000737
This is particularly valuable because it facilitates inference and visualisation. For instance,
each posterior sample for β generates a dose-DLT curve, and each of these nominates a
candidate for the MTD, being the dose with estimated Prob(DLT) closest to the toxicity
target. We can plot some of these generated curves, colouring each by the MTD that they
nominate, to visualise the level of uncertainty still inherent in the situation at this early stage.
R> fit %>%
R+ gather_draws(prob_tox[dose]) %>%
R+ group_by(.draw) %>%
R+ summarise(mtd = dose[which.min(abs(.value - target))]) -> mtd_candidates
R>
R> library(ggplot2)
R> fit %>%
R+ gather_draws(prob_tox[dose]) %>%
R+ left_join(mtd_candidates, by = '.draw') %>%
R+ filter(.draw <= 200) %>%
R+ ggplot(aes(x = dose, y = .value, group = .draw)) +
R+ geom_line(aes(col = as.factor(mtd)), alpha = 0.5) +
R+ geom_hline(yintercept = target, col = 'red', linetype = 'dashed') +
R+ labs(title = 'The identify of the MTD is still shrouded in mystery',
R+ y = 'Prob(DLT)', col = 'MTD') +
R+ theme(legend.position = 'bottom')
We plot just 200 curves to avoid saturating the plot. We see that curves that nominate each
of the five doses as the implied MTD are readily generated.
Using each of the posterior dose-DLT curves, let us calculate the posterior probability that
each dose is the MTD according to this model.
R> mtd_candidates %>%
R+ count(mtd) %>%
R+ mutate(prob_mtd = n / sum(n))
# A tibble: 5 x 3
mtd n prob_mtd
<int> <int> <dbl>
1 1 172 0.043
2 2 296 0.074
3 3 643 0.161
4 4 984 0.246
5 5 1905 0.476
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Figure 1: Posterior dose-toxicity curves generated by a CRM model fit to five patients’ data.
This matches the ProbMTD statistics in the model output above.
Yap et al. (2017) introduced dose transition pathways (DTPs) as the link between model-based
statistical dose-finding algorithms and simple decision making. A pathway in a dose-finding
trial is simply a sequence of doses that were delivered to patients and the outcomes that the
patients experienced.
Consider a trial that has already treated four patients in two cohorts:
R> outcomes <- '2NN 3TN'
Beyond questioning what dose will be advised for the third cohort, we might wonder about all
the doses could possibly be advised for the fourth and fifth cohorts. This might have material
consequences for the amount of drug that is to be manufactured and shipped to sites. trialr
provides flexible methods to automate such analyses.
For the purposes of this example, let us assume we are using the empiric model form and a
unit normal prior on β, and the following parameters:
R> skeleton <- c(0.05, 0.15, 0.25, 0.4, 0.6)
R> target <- 0.25
We calculate DTPs using the crm_dtps method:
R> paths1 <- crm_dtps(skeleton = skeleton, target = target, model = 'empiric',
R+ cohort_sizes = c(3, 3), previous_outcomes = outcomes,
R+ beta_sd = 1, refresh = 0)
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This function uses many of the same parameters as stan_crm. The previous_outcomes
parameter describes the path the trial has already taken; each calculated future path starts
from here. It can be omitted to reflect a trial that has not yet started. The cohort_sizes
parameter controls the number and size of future cohorts to consider. Each cohort of n may
result in 0, 1, 2,. . . , or n patients experiencing DLT. Thus calculating transitions for two
future cohorts of three patients, as above, yields 16 possible paths.
At the end of each cohort, there is a dose selection decision. By default, CRM models choose
the dose with posterior mean probability of toxicity closest to the target. However, in practice,
trialists may want to tailor this decision.
Custom dose selection is supported in crm_dtps via the user_dose_func parameter. For
instance, investigators may want to prevent the skipping of untested doses in escalalation, or
build in the facility to stop a trial early if there is sufficient evidence that a reference dose
is excessively toxic. Both of these design aspects were used in a recently published dose-
escalation trial in acute myeloid leukaemia (Craddock, Slade, De Santo, Wheat, Ferguson,
Hodgkinson, Brock, Cavenagh, Ingram, Dennis, Malladi, Siddique, Mussai, and Yap 2019)
and they are provided in trialr by the careful_escalation function. It prevents skipping
in escalation by recommending, where appropriate, the next highest dose to the maximum
that has yet been used. For instance, if the default behaviour is to escalate from dose 2 to
dose 4 without having tested dose 3, careful_escalation will instead recommend dose 3.
Additionally, it returns NA if a reference dose is detected to be too toxic and this is interpreted
by crm_dtps as the sign that this trial path should stop. Users are free to provide any
delegate function via user_dose_func that takes a dose_finding_fit as the sole parameter
and returns either an integer dose-level or NA. We re-calculate those paths using our custom
dose function:
R> paths2 <- crm_dtps(skeleton = skeleton, target = target, model = 'empiric',
R+ cohort_sizes = c(3, 3), previous_outcomes = outcomes,
R+ user_dose_func = function(x) {
R+ careful_escalation(x, tox_threshold = target + 0.1,
R+ certainty_threshold = 0.7,
R+ reference_dose = 1)
R+ }, beta_sd = 1, seed = 123, refresh = 0)
Here, a pathway will stop if ever
Pr(F (d1, β) > 0.35|D) > 0.7, (1)
i.e. if there is at least a 70% chance that the probability of DLT at the lowest dose exceeds
35%.
These paths are shown in Figure 2. Code to recreate this graph appears in the Appendix. We
see that the subsequent path 2TTT 1TTT yields the understandable decision to stop, but that
every other path selects a dose. We will only advise as high as dose 4 if no DLTs are seen in
the next 6 patients. This level of foresight and transparency underpins our motivation to use
dose pathways, particularly via an effective visualisation like Figure 2.
The returned object, paths2, has type dose_finding_paths and contains model fits at each
node on each pathway, as well as information on the tree structure. This is perhaps best
viewed as a tibble:
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Figure 2: Dose transition pathways for the next two cohorts of three patients in a dose-finding
trial using a CRM design.
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R> library(tibble)
R> paths2_df <- as_tibble(paths2)
R> paths2_df %>% head()
# A tibble: 6 x 8
.node .parent .depth outcomes next_dose fit parent_fit dose_index
<dbl> <dbl> <dbl> <chr> <dbl> <list> <list> <list>
1 1 NA 0 "" 2 <crm_fit> <NULL> <dbl [5]>
2 2 1 1 NNN 3 <crm_fit> <crm_fit> <dbl [5]>
3 3 2 2 NNN 4 <crm_fit> <crm_fit> <dbl [5]>
4 4 1 1 NNT 2 <crm_fit> <crm_fit> <dbl [5]>
5 5 4 2 NNN 3 <crm_fit> <crm_fit> <dbl [5]>
6 6 1 1 NTT 1 <crm_fit> <crm_fit> <dbl [5]>
Each node in the graph has a single row in this table. The variables that define the tree
structure are prefixed with a period. Whilst this tall format is useful for some purposes, like
creating graphs like Figure 2, dose-transition pathways are perhaps most intuitively tabulated
in a wide format. That task is accomplished by the spread_paths function, that will join
.node to .parent at each .depth to create a wide view of DTPs. For example,
R> spread_paths(paths2_df %>% select(-fit, -parent_fit, -dose_index))
# A tibble: 16 x 6
outcomes0 next_dose0 outcomes1 next_dose1 outcomes2 next_dose2
<chr> <dbl> <chr> <dbl> <chr> <dbl>
1 "" 2 NNN 3 NNN 4
2 "" 2 NNN 3 NNT 3
3 "" 2 NNN 3 NTT 2
4 "" 2 NNN 3 TTT 2
5 "" 2 NNT 2 NNN 3
6 "" 2 NNT 2 NNT 2
7 "" 2 NNT 2 NTT 1
8 "" 2 NNT 2 TTT 1
9 "" 2 NTT 1 NNN 2
10 "" 2 NTT 1 NNT 1
11 "" 2 NTT 1 NTT 1
12 "" 2 NTT 1 TTT 1
13 "" 2 TTT 1 NNN 1
14 "" 2 TTT 1 NNT 1
15 "" 2 TTT 1 NTT 1
16 "" 2 TTT 1 TTT NA
In this view, paths can be read horizontally. This confirms the dose choices shown in Figure
2. Had we retained fit in the frame that was passed to spread_paths, there would also be
columns fit0, fit1 and fit2 in the table above. These functions create a rich and flexible
method for working with paths in CRM trials. We demonstrate a similar approach in the
next section with EffTox.
Journal of Statistical Software 15
Parameter Mean Standard deviation
α -7.9593 3.5487
β 1.5482 3.5018
γ 0.7367 2.5423
ζ 3.4181 2.4406
η 0 0.2
ψ 0 1
Table 2: Normal prior hyperparameters used by Thall et al. (2014).
Fitting TITE-CRM models is also supported in trialr, again through the stan_crm function.
The outcome syntax used above, however, ceases to be succinct and useful when each patient
is associated an individual weight. Thus, when fitting the TITE-CRM, we provide vectors for
the doses given, the binary toxicity outcomes observed, and the weight for each observation.
For instance, in the example below we calculate the next dose in a trial that has partially
evaluated four patients at dose 3, as described by Cheung (2011, p.124). No patient has yet
experienced DLT but they are between 28 and 73 days through a 126-day evaluation window.
R> fit <-stan_crm(skeleton = c(0.05, 0.12, 0.25, 0.40, 0.55), target = 0.25,
R+ doses_given = c(3, 3, 3, 3),
R+ tox = c(0, 0, 0, 0),
R+ weights = c(73, 66, 35, 28) / 126,
R+ model = 'empiric', beta_sd = sqrt(1.34),
R+ seed = 123, refresh = 0)
R> fit$recommended_dose
[1] 4
We receive confirmation that the model advocates starting the next patient on dose 4.
3.3. EffTox
The EffTox model addresses the need for a dose-finding design that incorporates both efficacy
and toxicity outcomes. This is useful in modern oncology treatments like small molecules
and immunotherapies where, compared to chemotherapy, there is a weaker rationale for the
assumption that higher doses are associated with higher probabilities of success.
The probability model for EffTox described above uses six parameters. The extra complex-
ity naturally means it is more challenging to select priors. Thall et al. (2014) describe an
optimisation algorithm that selects hyperparameters for weakly informative normal priors on
α, β, γ and ζ so that the expected prior probabilities of efficacy and toxicity at each dose
match investigator-elicited values. The priors for η and ψ are fixed at N(0, 0.2) and N(0, 1)
respectively.
For example, expecting efficacy probabilities (0.2, 0.4, 0.6, 0.8, 0.9) and toxicity probabilities
(0.02, 0.04, 0.06, 0.08, 0.10) in a five-dose example, Thall et al. (2014) choose the parameter
priors in Table 2. The hyperparameter values can be calculated using the MD Anderson
EffTox software. This algorithm is not currently implemented in trialr.
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Figure 3: The prior standard deviations on alpha and beta in EffTox have relatively weak
effects on the prior beliefs on the location of optimal dose.
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Figure 4: The prior standard deviations on gamma and zeta in EffTox have relatively weak
effects on the prior beliefs on the location of optimal dose.
Journal of Statistical Software 17
Figures 3 and 4 show that the prior views on the location of the optimal dose do not change
materially for modest changes in the values of the standard deviation hyperparameters. In
each, the value of the non-varying parameters takes the value listed in Table 2. We see in
each panel of each plot that dose-level 5 is overwhelmingly expected to have the highest utility
score. As the standard deviation hyperparameters increase, more probability is placed on dose
1 being optimal. The probabilities of doses 2 to 4 barely change.
By way of illustration, let us continue with Thall et al.’s parameterisation. The authors seek
the most attractive dose of a drug from (1, 2, 4, 6.6, 10) mcL/kg that satisfies both
Pr(piE(xi) > 0.5|D) > 0.1 (2)
and
Pr(piT (xi) < 0.3|D) > 0.1 (3)
where the neutral utility contour intersects the hinge points (pi∗1,E , 0) = (0.5, 0), (1, pi
∗
2,T ) =
(1, 0.65) and (pi∗3,E , pi
∗
3,T ) = (0.7, 0.25). Let us fit this model to the outcomes 1NNN 2ENN:
R> outcomes <- '1NNN 2ENN'
R>
R> fit <- stan_efftox(outcome_str = outcomes,
R+ real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
R+ efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
R+ p_e = 0.1, p_t = 0.1, eff0 = 0.5, tox1 = 0.65,
R+ eff_star = 0.7, tox_star = 0.25,
R+ alpha_mean = -7.9593, alpha_sd = 3.5487,
R+ beta_mean = 1.5482, beta_sd = 3.5018,
R+ gamma_mean = 0.7367, gamma_sd = 2.5423,
R+ zeta_mean = 3.4181, zeta_sd = 2.4406,
R+ eta_mean = 0, eta_sd = 0.2,
R+ psi_mean = 0, psi_sd = 1,
R+ seed = 123, refresh = 0)
R> fit
Patient Dose Toxicity Efficacy
1 1 1 0 0
2 2 1 0 0
3 3 1 0 0
4 4 2 0 1
5 5 2 0 0
6 6 2 0 0
Dose N ProbEff ProbTox ProbAccEff ProbAccTox Utility Acceptable ProbOBD
1 1 3 0.0506 0.00685 0.003 0.997 -0.911 FALSE 0.0158
2 2 3 0.2700 0.00356 0.130 1.000 -0.466 TRUE 0.0075
3 3 0 0.7287 0.01399 0.798 0.988 0.434 TRUE 0.0862
4 4 0 0.8667 0.05261 0.911 0.940 0.648 FALSE 0.1893
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Figure 5: Utility contour plot for the described EffTox example after observing 1NNN 2ENN.
5 5 0 0.9121 0.11791 0.938 0.861 0.637 FALSE 0.7013
The model recommends selecting dose-level 3.
The dose most likely to be the OBD is 5.
Model entropy: 0.88
The parameters eff0, tox1, eff_star and tox_star reflect the values pi∗1,E , pi
∗
2,T , (pi
∗
3,E and
pi∗3,T .
We see that dose-level 3 is recommended for the next cohort. Even though doses 4 and 5
have higher estimated utility scores, they are not recommended because dose 3 has not yet
been given. ProbAccEff and ProbAccTox estimate the probability that the estimated rates
of efficacy and toxicity are the desirable sides of 0.5 and 0.3, respectively. Dose 1 is not
acceptable because ProbAccEff is less than 0.1. The utility values implied by the posterior
mean probabilities of efficacy and toxicity are shown in Figure 5, created using the command:
R> efftox_contour_plot(fit)
Doses that are closer to the lower-right corner of Figure 5, reflecting guarenteed efficacy and
no toxicity, have higher utility scores.
Using the posterior samples of the utility scores at each dose, it is possible to estimate the
probability that each dose is superior to the others. The following superiority matrix shows
the implied probability that the dose represented by the column has greater utility than the
dose represented by the row:
R> efftox_superiority(fit)
1 2 3 4 5
1 NA 0.98125 0.97800 0.97350 0.96800
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2 0.01875 NA 0.97575 0.96075 0.93150
3 0.02200 0.02425 NA 0.89200 0.81300
4 0.02650 0.03925 0.10800 NA 0.70825
5 0.03200 0.06850 0.18700 0.29175 NA
Thus, we can be quite sure that dose 4 has higher utility than doses 1 to 3, but we are rather
more unsure about whether it has higher utility than dose 5. This is confirmed by Figure 5.
trialr also supports the calculation of dose-transition pathways for EffTox. The number of
events that patients may experience is now four (E, T, B or N), compared to the two events
(T or N) that were possible in the CRM examples. As such, the number of distinct pathways
that can be taken increases very quickly. For instance, the number of outcome combinations
for a cohort of three is 20, so that two cohorts of three generate 400 pathways. This is too
many to represent on a graph. To illustrate, we consider the next cohort of three patients in
our trial above:
R> paths <- efftox_dtps(cohort_sizes = c(3), previous_outcomes = outcomes,
R+ real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
R+ efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
R+ p_e = 0.1, p_t = 0.1, eff0 = 0.5, tox1 = 0.65,
R+ eff_star = 0.7, tox_star = 0.25,
R+ alpha_mean = -7.9593, alpha_sd = 3.5487,
R+ beta_mean = 1.5482, beta_sd = 3.5018,
R+ gamma_mean = 0.7367, gamma_sd = 2.5423,
R+ zeta_mean = 3.4181, zeta_sd = 2.4406,
R+ eta_mean = 0, eta_sd = 0.2,
R+ psi_mean = 0, psi_sd = 1,
R+ next_dose = 3, seed = 123, refresh = 0)
Again, the returned object has type dose_finding_paths so, as with the CRM examples,
we can invoke as_tibble and spread_paths on paths. The associated fit and parent_fit
objects are each of type efftox_fit. These can be used with map-like functions from purrr
(Henry and Wickham 2019) for flexible analysis of DTP objects:
R> library(tidyr)
R> library(purrr)
R>
R> as_tibble(paths) %>%
R+ filter(.depth > 0) %>%
R+ mutate(prob_obd = map(fit, 'prob_obd'),
R+ parent_prob_obd = map(parent_fit, 'prob_obd')) %>%
R+ select(outcomes, dose_index, prob_obd, parent_prob_obd) %>%
R+ unnest %>%
R+ mutate(prob_obd_delta = prob_obd - parent_prob_obd) %>%
R+ filter(dose_index == 5)
# A tibble: 20 x 5
outcomes dose_index prob_obd parent_prob_obd prob_obd_delta
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<chr> <int> <dbl> <dbl> <dbl>
1 BBB 5 0.136 0.701 -0.565
2 BBE 5 0.061 0.701 -0.640
3 BBN 5 0.176 0.701 -0.525
4 BBT 5 0.316 0.701 -0.385
5 BEE 5 0.142 0.701 -0.559
6 BEN 5 0.21 0.701 -0.491
7 BET 5 0.164 0.701 -0.538
8 BNN 5 0.323 0.701 -0.378
9 BNT 5 0.274 0.701 -0.427
10 BTT 5 0.397 0.701 -0.305
11 EEE 5 0.677 0.701 -0.0245
12 EEN 5 0.756 0.701 0.0550
13 EET 5 0.223 0.701 -0.478
14 ENN 5 0.788 0.701 0.0872
15 ENT 5 0.312 0.701 -0.389
16 ETT 5 0.280 0.701 -0.421
17 NNN 5 0.728 0.701 0.0272
18 NNT 5 0.329 0.701 -0.372
19 NTT 5 0.242 0.701 -0.460
20 TTT 5 0.287 0.701 -0.415
In the example above for instance, we illustrate how the views on dose-level 5, in particular
its chances of being the optimal dose, can change materially based on the outcome of the next
cohort of three patients. This demonstrates the lack of information currently in the model in
this situation, particularly the sensitivity of the estimated identity of the OBD to incidence
of any toxicity.
The left panel of Figure 6 shows the paths for the next cohort of three. After only nine patients,
there are three paths that advocate stopping. These are all paths that see considerable toxicity
in cohort 3. The right panel of Figure 6 shows the paths generated by the next two cohorts
of one patient. Code to create these graphs appears in the Appendix.
The function efftox_dtps also accepts a custom dose selection function via the user_dose_func
parameter. The fit object recorded at each node in paths has type efftox_fit, a subclass
of dose_finding_fit. The user_dose_func delegate should take an efftox_fit as the sole
parameter and return an integer dose-level for the next patient, or NA to advocate stopping
the trial, mirroring the behaviour of the CRM example. We do not illustrate that here.
3.4. Augmented Binary method
To demonstrate the two-period Augmented Binary method for single arm trials, we will fit it
to a dataset drawn from one of the simulation scenarios used by Wason and Seaman (2013).
First, let us consider priors on the parameters.
We will consider two sets of priors to demonstrate the effect they have on the posterior. The
prior distributions in the first set are relatively informative:
R> informative_priors <- list(alpha_mean = 0, alpha_sd = 0.1,
R+ beta_mean = 0, beta_sd = 0.1,
Journal of Statistical Software 21
Figure 6: Dose pathways for the next cohort of three patients (left) and next two cohorts of
one patient (right) in an EffTox trial that has already seen ‘1NNN 2ENN‘.
R+ gamma_mean = 0, gamma_sd = 0.1,
R+ sigma_mean = 0, sigma_sd = 0.5,
R+ omega_lkj_eta = 1,
R+ alpha_d1_mean = 0, alpha_d1_sd = 0.5,
R+ gamma_d1_mean = 0, gamma_d1_sd = 0.25,
R+ alpha_d2_mean = 0, alpha_d2_sd = 0.5,
R+ gamma_d2_mean = 0, gamma_d2_sd = 0.25)
For the covariance matrix Σ, half-normal priors with parameters sigma_mean and sigma_sd
are used for the diagonal elements, and an LKJ prior is specified on the associated correlation
matrix, Ω. The parameter Ωη = 1 generates uniform beliefs on the correlation between y1
and y2. Values > 1 would reflect an expectation that correlations near 0 are more likely, and
vice-versa.
In constrast, the priors in the second set are relatively diffuse:
R> diffuse_priors <- list(alpha_mean = 0, alpha_sd = 1,
R+ beta_mean = 0, beta_sd = 1,
R+ gamma_mean = 0, gamma_sd = 1,
R+ sigma_mean = 0, sigma_sd = 1,
R+ omega_lkj_eta = 1,
R+ alpha_d1_mean = 0, alpha_d1_sd = 1,
R+ gamma_d1_mean = 0, gamma_d1_sd = 1,
R+ alpha_d2_mean = 0, alpha_d2_sd = 1,
R+ gamma_d2_mean = 0, gamma_d2_sd = 1)
Unit normal prior distributions may not immediately seem diffuse until we consider their
effect on the generated outcome distributions. Prior predictive outcomes generated by each
set of priors are shown in Figures 7 and 8. Code to create these figures are included in the
Appendix.
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Figure 7: Prior predictive tumour size ratios generated by two sets of prior parameters in the
two-period AugBin model.
We see in Figure 7 that the diffuse priors generate a far wider set of outcomes. In fact, log-
tumour-size ratios near 20 imply tumour growth that is many orders of magnitude greater
than what is feasible. Growth to this extent would imply that the patient could increase
their volume thousands of times over, a clear nonsense. The outcomes generated by the
informative priors are much more realistic. The baseline tumour sizes in cm are sampled from
a U(5, 10) distribution so that the expected tumour size in each set of priors is 7.5cm. Under
the informative priors, the expected tumour size at each post-baseline assessment is 12.5cm.
Under each set, the chances of tumour growth at each timepoint is roughly 50%.
Figure 8 shows the prior predictive probabilities of non-shrinkage failure generated by the two
prior sets at the interim timepoint. Once again, we see that extreme outcomes are generated
far too readily by the diffuse priors. In contrast, the informative priors generate probabilities
that are roughly uniform and not associated with baseline tumour size.
To demonstrate the AugBin model, we will fit it to a dataset randomly sampled using the
parameterisation described by Wason and Seaman (2013) in the first line of their Table 1.
We have parameters:
R> N <- 50
R> sigma <- 1
R> delta1 <- -0.356
R> mu <- c(0.5 * delta1, delta1)
R> Sigma = matrix(c(0.5 * sigma^2, 0.5 * sigma^2,
R+ 0.5 * sigma^2, sigma^2), ncol = 2)
R> alphaD <- -1.5
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Figure 8: Prior predictive probabilities of non-shrinkage failure generated by two sets of prior
parameters in the two-period AugBin model.
R> gammaD <- 0
That is, there are 50 patients, the expected tumour shrinkage at time 2 is exp(−0.356)− 1 =
30%, and the chances of non-shrinkage failure at each stage are logit−1(−1.5) = 18%. These
parameters generate data:
R> set.seed(123456)
R> y <- MASS::mvrnorm(n = N, mu, Sigma)
R> z0 <- runif(N, min = 5, max = 10)
R> z1 <- exp(y[, 1]) * z0
R> z2 <- exp(y[, 2]) * z0
R> d1 <- rbinom(N, size = 1, prob = gtools::inv.logit(alphaD + gammaD * z0))
R> d2 <- rbinom(N, size = 1, prob = gtools::inv.logit(alphaD + gammaD * z1))
R> tumour_size = data.frame(z0, z1, z2) # cm
R> non_shrinkage_failure <- data.frame(d1, d2)
The values in tumour_size reflect (z1, z2, z3) measured in cm.
To fit this data to the two-period, single-arm model, referred to as 2t-1a in trialr, we run
the command:
R> fit_diffuse <- stan_augbin(tumour_size, non_shrinkage_failure,
R+ model = '2t-1a', prior_params = diffuse_priors,
R+ seed = 123, refresh = 0)
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R> fit_inf <- stan_augbin(tumour_size, non_shrinkage_failure,
R+ model = '2t-1a', prior_params = informative_priors,
R+ seed = 123, refresh = 0)
The object returned by stan_fit has type augbin_fit.
The main benefit that Wason & Seaman identify for their method is the increase in efficiency
that comes from analysing the continuous tumour size variable rather than dichotomising
the information into a binary outcome. They calculate the width of the 95% confidence
interval (CI) for the probability of success under their method. They then do the same using
the dichotomised binary success variables, Si, using 30% shrinkage at time 2 and no non-
shrinkage failure as the criteria for success. They infer the increase in efficiency by comparing
the widths of the CI under each method from a large number of simulated trials. We can
recreate this type of analysis in trialr. Focusing on the model fit using the diffuse priors:
R> pred_diffuse <- predict(fit_diffuse, y2_upper = log(0.7))
R> pred_diffuse %>% head()
# A tibble: 6 x 8
id z0 z1 prob_success_samp prob_success lower upper ci_width
<int> <dbl> <dbl> <list> <dbl> <dbl> <dbl> <dbl>
1 1 5.99 16.0 <dbl [4,000]> 0.277 0.176 0.385 0.208
2 2 5.66 4.81 <dbl [4,000]> 0.223 0.141 0.318 0.177
3 3 9.32 5.59 <dbl [4,000]> 0.269 0.165 0.385 0.220
4 4 6.16 3.16 <dbl [4,000]> 0.218 0.136 0.316 0.180
5 5 5.57 10.2 <dbl [4,000]> 0.250 0.161 0.352 0.191
6 6 7.08 11.1 <dbl [4,000]> 0.275 0.186 0.374 0.188
We see that the estimated probabilities of success are approximately 25%, and vary slightly
depending on the baseline and interim tumour size measurements. The prob_success_samp
column contains the posterior samples of the probability of success for each patient. By
default, lower and upper contain posterior 2.5% and 97.5% quantiles of prob_success but
this can be changed by specifying the desired quantile probabilities using the probs argument.
We can also make inferences by analysing the dichotomised binary outcome:
R> pred_binary <- binary_prob_success(fit_diffuse, y2_upper = log(0.7),
R+ methods = 'exact')
R> pred_binary
method x n mean lower upper ci_width
1 exact 14 50 0.28 0.1623106 0.4249054 0.2625948
This function uses the binom (Dorai-Raj 2014) package.
We see that there were 14 responses in 50 patients, yielding a response rate of 28%. By
default, bounds for the 95% CI are shown but this can be tailored. The average decrease in
the widths of the 95% intervals is:
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Figure 9: Posterior predictions from the AugBin model to 50 simulated patients under two
different sets of priors. The orange lines show the mean and 0.95 CI derived from the binary
success variables.
R> mean(pred_diffuse$ci_width) / pred_binary$ci_width - 1
[1] -0.2262706
The reduction of approximately 23% in this single simulated iteration is higher than the
16.5% average reduction reported by Wason & Seaman comparing AugBin to the regular
binary method in this scenario.
These inferences for both AugBin fits are shown in Figure 9. The points show the estimated
probability of success, and the vertical bars the 95% posterior credible intervals. The orange
lines show the estimates from the ordinary binary approach, with the dashed line showing the
mean and the dotted lines the 95% confidence interval boundaries.
We see a slight positive relationship in estimated success probability and baseline tumour
size. This is a random manifestation in the sampled dataset. We see that the intervals are
generally narrower with the AugBin method, particularly so under the informative priors.
The average credible interval width under the informative priors is 36% narrower than that
from the binary method. This suggests the strong effect the priors are having.
Comparing the two sets of fitted values from the AugBin models, we see that the estimates
are generally a few percent lower under the informtive priors. In fact, a simulation study with
1,000 iterations reveals that the estimated probabilities of success under these informative
priors are biased downwards by 4.5% on average, and that the coverage of 95% posterior
credible intervals is only 71.7%. In contrast, simulations under the diffuse priors reveal down-
ward bias of approximately 1.5% and 95% posterior interval coverage of 92.7%, much closer
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to the nominal value. Code to run the simulation study appears in the GitHub repository of
this article at https://github.com/brockk/trialr-jss.
As an R-user might expect, the predict function allows the specification of newdata to obtain
predictions for custom cases:
R> predict(fit_diffuse, newdata = data.frame(z0 = 5:10, z1 = 4:9),
R+ y2_upper = log(0.7))
# A tibble: 6 x 8
id z0 z1 prob_success_samp prob_success lower upper ci_width
<int> <int> <int> <list> <dbl> <dbl> <dbl> <dbl>
1 1 5 4 <dbl [4,000]> 0.210 0.124 0.312 0.188
2 2 6 5 <dbl [4,000]> 0.228 0.149 0.320 0.171
3 3 7 6 <dbl [4,000]> 0.247 0.166 0.336 0.171
4 4 8 7 <dbl [4,000]> 0.265 0.177 0.362 0.185
5 5 9 8 <dbl [4,000]> 0.282 0.180 0.394 0.214
6 6 10 9 <dbl [4,000]> 0.298 0.177 0.436 0.260
Function parameters also allow users to specify different shrinkage thresholds for response at
interim and final timepoints.
4. Discussion
The trialr package exploits the power of Stan to offer full Bayesian inference to clinical trialists
and researchers. We have illustrated this using the CRM and EffTox designs for conducting
dose-finding trials. One of the cornerstones of our approach is using posterior samples for
intuitive and flexible inference. For instance, having access to posterior samples in a utility-
maximising design like EffTox allowed us to directly calculate the probabilities of superiority
of the doses. Without posterior samples, that calculation would have been more challenging.
The other core tenets of our approach include using modern tidyverse (Wickham 2017)
classes and methods and relying on visualisation to convey insights. By using tidybayes (Kay
2019), posterior samples are available in tidy formats, convenient for further analysis via
dplyr (Wickham, Franc¸ois, Henry, and Mu¨ller 2019) and purrr (Henry and Wickham 2019)
functions, as we have demonstrated in several examples. We have included plots using ggplot2
(Wickham 2016) and graphs using DiagrammeR (Iannone 2018).
We have demonstrated functions and classes dedicated to calculating dose transition path-
ways in dose-finding trials. Our approach will work not just for CRM and EffTox but for
general phase I and phase I/II designs. In future releases of trialr, we will provide the same
funcionality for the Escalation with Overdose Control design (Tighiouart and Rogatko 2010)
and the seamless phase I/II design of Wages and Tait (2015). Calculating dose paths for
Wages & Tait’s design may initially seem questionable because their method uses adaptive
randomisation to allocate patients to doses inferred to be tolerable. If the dose recommended
is random, what point is there in considering future paths? Although the dose is random,
the way that future randomisation probabilities are adapted in response to outcomes will
still be of interest. Our use of tibble allows that a vector may be the item of interest in a
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DTP analysis. For example, it would be possible to analyse adaptive randomisation proba-
bilities in Wages & Tait’s design in a manner similar to how we analysed above changes in
the probability of a dose being the OBD.
We have not presented methods for conducting dose-finding simulation studies. Though these
would be simple to perform using trialr, users may be put off by the computational overhead of
performing MCMC sampling. For the purposes of illustration, let us assume that model fitting
by MCMC sampling takes 1 second, and that simulations would investigate performance of
a dose-finding trial using 30 patients, evaluated in cohorts of three. Each simulated replicate
would require 10 model fits, taking 10 seconds. A study of 1000 replicates would take over 2.5
hours. By time alone, this is vastly inferior to functions that conduct simulations using non-
MCMC methods such as those offered by dfcrm (Cheung 2013). Nevertheless, simulations
remain a key tool for clinical trialists to justify the use of such adaptive designs, and will be
developed in trialr in future.
We also demonstrated in this manuscript the AugBin model of Wason and Seaman (2013)
for single-arm trials. The authors also include a two-arm version suitable for randomised
trials. They also latterly introduced versions of the model suitable for trials with an arbitrary
number of post-baseline assessments. These variants are not currently in trialr but they will
be added in the future, supporting the same generic functions.
We investigated two sets of priors with the AugBin model. The diffuse priors we used could
hardly be described as generative or representing any reasonable person’s beliefs because
they yield prior predictive outcomes that are plainly implausible. However, our informative
priors that are broadly generative of plausible outcomes a-priori, exhibit possibly undesirable
numerical performance, with relatively large bias and low interval coverage. Learning how to
set priors for this Bayesian version of the AugBin model is an area worthy of further research.
Despite being an R package, the Stan implementations of the models in trialr can be used
with StataStan and PyStan to fit the models in Stata and Python respectively.
trialr is available at https://CRAN.R-project.org/package=trialr. Source code is avail-
able on GitHub at https://github.com/brockk/trialr. The source for this article is avail-
able at https://github.com/brockk/trialr-jss.
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6. Appendix
6.1. Reproducing Figures in CRM sections
The following code creates Figure 2. The command render_graph displays the graph in the
RStudio Viewer.
R> library(tibble)
R> library(dplyr)
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R> paths2_df <- as_tibble(paths2)
R>
R> library(DiagrammeR)
R> # DiagrammeR requires data.frames of nodes and edges to create a graph.
R> paths2_df %>%
R> transmute(id = .node,
R> type = NA,
R> label = case_when(
R> is.na(next_dose) ~ 'Stop',
R> TRUE ~ next_dose %>% as.character()),
R> shape = 'circle',
R> fillcolor = case_when(
R> next_dose == 1 ~ 'slategrey',
R> next_dose == 2 ~ 'skyblue1',
R> next_dose == 3 ~ 'royalblue1',
R> next_dose == 4 ~ 'orchid4',
R> next_dose == 5 ~ 'royalblue4',
R> is.na(next_dose) ~ 'red'
R> )
R> ) -> nodes_df
R> paths2_df %>%
R> filter(!is.na(.parent)) %>%
R> select(from = .parent, to = .node, label = outcomes) %>%
R> mutate(rel = "leading_to") -> edges_df
R> graph <- create_graph(nodes_df = nodes_df, edges_df = edges_df)
R> render_graph(graph)
6.2. Reproducing Figures in EffTox sections
The following code creates Figures 3 and 4.
R> library(tibble)
R> library(purrr)
R> library(dplyr)
R> library(tidyr)
R> library(ggplot2)
R>
R> fit_thall_2014 <- function(outcomes, alpha_sd, beta_sd, gamma_sd, zeta_sd) {
R> stan_efftox(outcome_str = outcomes,
R> real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
R> efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
R> p_e = 0.1, p_t = 0.1, eff0 = 0.5, tox1 = 0.65,
R> eff_star = 0.7, tox_star = 0.25,
R> alpha_mean = -7.9593, alpha_sd = alpha_sd,
R> beta_mean = 1.5482, beta_sd = beta_sd,
R> gamma_mean = 0.7367, gamma_sd = gamma_sd,
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R> zeta_mean = 3.4181, zeta_sd = zeta_sd,
R> eta_mean = 0, eta_sd = 0.2,
R> psi_mean = 0, psi_sd = 1,
R> seed = 123, refresh = 0)
R> }
R>
R> expand.grid(
R> alpha_sd = c(2, 3, 4),
R> beta_sd = c(2, 3, 4),
R> gamma_sd = 2.5423,
R> zeta_sd = 2.4406
R> ) %>%
R> as_tibble() %>%
R> mutate(fit = pmap(list(alpha_sd, beta_sd, gamma_sd, zeta_sd),
R> fit_thall_2014, outcomes = ''),
R> series = rownames(.)) -> prior_fits1
R>
R> prior_fits1 %>%
R> mutate(
R> dose = map(fit, 'dose_indices'),
R> prob_obd = map(fit, 'prob_obd'),
R> entropy = map_dbl(fit, 'entropy')
R> ) %>%
R> select(-fit) %>%
R> unnest %>%
R> ggplot(aes(x = dose, y = prob_obd, fill = entropy)) +
R> geom_col() +
R> facet_grid(~ alpha_sd ~ beta_sd) +
R> labs(y = 'Prob(dose has maximal utility)',
R> title = 'Effect of prior SD of alpha (rows) and beta (columns)') +
R> theme(legend.position = 'bottom')
R> expand.grid(alpha_sd = 3.5487,
R> beta_sd = 3.5018,
R> gamma_sd = c(2, 3, 4),
R> zeta_sd = c(2, 3, 4)
R> ) %>%
R> as_tibble() %>%
R> mutate(fit = pmap(list(alpha_sd, beta_sd, gamma_sd, zeta_sd),
R> fit_thall_2014, outcomes = ''),
R> series = rownames(.)) -> prior_fits2
R>
R> prior_fits2 %>%
R> mutate(
R> dose = map(fit, 'dose_indices'),
R> prob_obd = map(fit, 'prob_obd'),
R> entropy = map_dbl(fit, 'entropy')
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R> ) %>%
R> select(-fit) %>%
R> unnest %>%
R> ggplot(aes(x = dose, y = prob_obd, fill = entropy)) +
R> geom_col() +
R> facet_grid(~ gamma_sd ~ zeta_sd) +
R> labs(y = 'Prob(dose has maximal utility)',
R> title = 'Effect of prior SD of gamma (rows) and zeta (columns)') +
R> theme(legend.position = 'bottom')
The following code creates Figure 6.
R> outcomes <- '1NNN 2ENN'
R>
R> # Left-hand plot
R> paths <- efftox_dtps(cohort_sizes = c(3), previous_outcomes = outcomes,
R> real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
R> efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
R> p_e = 0.1, p_t = 0.1, eff0 = 0.5, tox1 = 0.65,
R> eff_star = 0.7, tox_star = 0.25,
R> alpha_mean = -7.9593, alpha_sd = 3.5487,
R> beta_mean = 1.5482, beta_sd = 3.5018,
R> gamma_mean = 0.7367, gamma_sd = 2.5423,
R> zeta_mean = 3.4181, zeta_sd = 2.4406,
R> eta_mean = 0, eta_sd = 0.2,
R> psi_mean = 0, psi_sd = 1,
R> next_dose = 3, seed = 123, refresh = 0)
R>
R> paths_df <- as_tibble(paths)
R> paths_df %>%
R> transmute(id = .node,
R> type = NA,
R> label = case_when(
R> is.na(next_dose) ~ 'Stop',
R> TRUE ~ next_dose %>% as.character()),
R> shape = 'circle',
R> fillcolor = case_when(
R> next_dose == 1 ~ 'slategrey',
R> next_dose == 2 ~ 'skyblue1',
R> next_dose == 3 ~ 'royalblue1',
R> next_dose == 4 ~ 'orchid4',
R> next_dose == 5 ~ 'royalblue4',
R> is.na(next_dose) ~ 'red'
R> )
R> ) -> nodes_df
R>
R> paths_df %>%
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R> filter(!is.na(.parent)) %>%
R> select(from = .parent, to = .node, label = outcomes) %>%
R> mutate(rel = "leading_to") -> edges_df
R>
R> graph <- create_graph(nodes_df = nodes_df, edges_df = edges_df)
R> render_graph(graph)
R>
R> # Right-hand plot
R> paths <- efftox_dtps(cohort_sizes = c(1, 1), previous_outcomes = outcomes,
R> next_dose = 3, real_doses = c(1.0, 2.0, 4.0, 6.6, 10.0),
R> efficacy_hurdle = 0.5, toxicity_hurdle = 0.3,
R> p_e = 0.1, p_t = 0.1, eff0 = 0.5, tox1 = 0.65,
R> eff_star = 0.7, tox_star = 0.25,
R> alpha_mean = -7.9593, alpha_sd = 3.5487,
R> beta_mean = 1.5482, beta_sd = 3.5018,
R> gamma_mean = 0.7367, gamma_sd = 2.5423,
R> zeta_mean = 3.4181, zeta_sd = 2.4406,
R> eta_mean = 0, eta_sd = 0.2,
R> psi_mean = 0, psi_sd = 1,
R> seed = 123, refresh = 2000)
R> paths_df <- as_tibble(paths)
R>
R> paths_df %>%
R> transmute(id = .node,
R> type = NA,
R> label = case_when(
R> is.na(next_dose) ~ 'Stop',
R> TRUE ~ next_dose %>% as.character()),
R> shape = 'circle',
R> fillcolor = case_when(
R> next_dose == 1 ~ 'slategrey',
R> next_dose == 2 ~ 'skyblue1',
R> next_dose == 3 ~ 'royalblue1',
R> next_dose == 4 ~ 'orchid4',
R> next_dose == 5 ~ 'royalblue4',
R> is.na(next_dose) ~ 'red'
R> )
R> ) -> nodes_df
R>
R> paths_df %>%
R> filter(!is.na(.parent)) %>%
R> select(from = .parent, to = .node, label = outcomes) %>%
R> mutate(rel = "leading_to") -> edges_df
R>
R> graph <- create_graph(nodes_df = nodes_df, edges_df = edges_df)
R> render_graph(graph)
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6.3. Reproducing Figures in AugBin sections
The following code produce Figures 7.
R> set.seed(123)
R> diffuse_prior_pred_data <- do.call(prior_predictive_augbin_2t_1a,
R> append(diffuse_priors,
R> list(num_samps = 1000)))
R> inf_prior_pred_data <- do.call(prior_predictive_augbin_2t_1a,
R> append(informative_priors,
R> list(num_samps = 1000)))
R>
R> library(stringr)
R> library(tidyr)
R>
R> # Visualise tumour sizes
R> bind_rows(
R> diffuse_prior_pred_data %>% mutate(Prior = 'Diffuse'),
R> inf_prior_pred_data %>% mutate(Prior = 'Informative')
R> ) %>%
R> select(id, Prior, y0, y1, y2) %>%
R> gather(assessment, y, -id, -Prior) %>%
R> mutate(time = str_extract(assessment, '\\d+') %>% as.integer()) %>%
R> ggplot(aes(x = time, y = y)) +
R> geom_line(aes(group = id), alpha = 0.3, col = 'darkgray') +
R> geom_hline(yintercept = log(0.7), col = 'orange', linetype = 'dashed') +
R> scale_x_continuous(breaks = 0:2) +
R> labs(y = 'log(tumour size ratio)') +
R> facet_wrap(~ Prior)
The following code produce Figures 8.
R> bind_rows(
R> diffuse_prior_pred_data %>% mutate(Prior = 'Diffuse'),
R> inf_prior_pred_data %>% mutate(Prior = 'Informative')
R> ) %>%
R> ggplot(aes(x = z0, y = prob_d1)) +
R> geom_point() + geom_smooth(method = 'gam') +
R> labs(x = 'Baseline tumour size (cm)',
R> y = 'Prob(Non-shrikage failure at time 1)') +
R> facet_wrap(~ Prior)
The following code produces Figure 9.
R> pred_inf <- predict(fit_inf, y2_upper = log(0.7))
R> pred_diffuse <- predict(fit_diffuse, y2_upper = log(0.7))
R> pred_binary <- binary_prob_success(fit_diffuse,
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R> y2_upper = log(0.7),
R> methods = 'exact')
R>
R> pred_diffuse %>%
R> ggplot(aes(x = z0, y = prob_success, col = z1)) +
R> geom_point() +
R> geom_linerange(aes(ymin = lower, ymax = upper)) +
R> geom_hline(yintercept = pred_binary$mean, col = 'orange',
R> linetype = 'dashed') +
R> geom_hline(yintercept = pred_binary$lower, col = 'orange',
R> linetype = 'dotted') +
R> geom_hline(yintercept = pred_binary$upper, col = 'orange',
R> linetype = 'dotted') +
R> ylim(0, 0.75) +
R> labs(x = 'Baseline tumour size (cm)', y = 'Prob(Success)',
R> col = 'Interim size (cm)', title = 'Diffuse') +
R> theme(legend.position = 'bottom') -> aubgin_diffuse_plot
R>
R> pred_inf %>%
R> ggplot(aes(x = z0, y = prob_success, col = z1)) +
R> geom_point() +
R> geom_linerange(aes(ymin = lower, ymax = upper)) +
R> geom_hline(yintercept = pred_binary$mean, col = 'orange',
R> linetype = 'dashed') +
R> geom_hline(yintercept = pred_binary$lower, col = 'orange',
R> linetype = 'dotted') +
R> geom_hline(yintercept = pred_binary$upper, col = 'orange',
R> linetype = 'dotted') +
R> ylim(0, 0.75) +
R> labs(x = 'Baseline tumour size (cm)', y = 'Prob(Success)',
R> col = 'Interim size (cm)', title = 'Informative') +
R> theme(legend.position = 'bottom') -> aubgin_inf_plot
R>
R> gridExtra::grid.arrange(aubgin_diffuse_plot, aubgin_inf_plot, ncol = 2)
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